Biotech & pharma press releases — Press Release Database

Healthcare · Biotech & pharma

JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA)

Warsaw, Poland – October 19, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotechnology company advancing first-in-class therapies for immune-mediated diseases and cancer, today announces that the first patients have been dosed in its Phase 1b trial of nebaprubart, an investigational potential first-in-class anti-CD89 antagonist, for the treatment of seropositive rheumatoid arthritis.

Oct 19 · 05:00GlobeNewswire

Healthcare · Biotech & pharma

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

Press release – No. 21 / 2026

Oct 19 · 05:00GlobeNewswire

Healthcare · Biotech & pharma

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid.

Oct 19 · 05:00GlobeNewswire

Healthcare · Industrial

NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline

Collaboration spans Copper-67 supply and radiopharmaceutical manufacturing from clinical development through commercialization. Partnership leverages NorthStar's vertically integrated campus, combining proprietary Copper-67 production technology, cGMP manufacturing, and commercial-scale infrastructure. BASEL, Switzerland

Oct 19 · 04:00Business Wire

Energy · Biotech & pharma

Infleqtion Convenes Business Leaders in London to Chart Quantum Commercial Value

Quantum Application Forum, 3 November 2026, gives executives a practical view of where quantum can create commercial value Summary : Real-world quantum use cases: One-day forum on quantum applications for business and public sector priorities in financial services, healthcare, pharmaceuticals, materials science, energy an

Oct 19 · 04:00Business Wire

Healthcare · Biotech & pharma

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv")...

Oct 19 · 02:00PR Newswire

Healthcare · Biotech & pharma

/C O R R E C T I O N - AbbVie/

In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its...

Oct 19 · 01:18AbbVie

Biotech & pharma

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera ™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera's ESMO program AUSTIN, Texas, October 18, 2026 --( BUS

Oct 18 · 22:10Business Wire

Healthcare · Biotech & pharma

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO...

Oct 18 · 22:10PR Newswire

Finance · Healthcare

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for...

Oct 18 · 22:05Eli Lilly and Company